Nls pharmaceutics announces an r&d update webcast to review the company's growing portfolio of pre-clinical compounds

Management to discuss pipeline goals and development strategies across four preclinical and 2 clinical programs across multiple central nervous system (cns) disorders nls to webcast its r&d day event tuesday, january 31 at 10:00am est zurich, switzerland / accesswire / january 12, 2023 / nls pharmaceutics ltd. (nasdaq:nlsp, nlspw) ("nls" or the "company"), a swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced plans to showcase its global strategic r&d progress and platform, as well as its product candidate and pipeline goals for 2023, with a focus on rare and complex cns disorders with unmet medical needs.
NLSP Ratings Summary
NLSP Quant Ranking